News Releases

News Releases

Synteract Presents Webinar: Utilizing Inventive Biostatistical Methods to Enhance Rare Disease Trials

RESEARCH TRIANGLE PARK, NC – September 17, 2019 – Synteract, an innovative CRO partnering with biotech and pharma companies to bring new medicines to market, will host a webinar on “Utilizing Inventive Biostatistical Methods to Enhance Rare Disease Trials.” This complimentary webinar will be presented on Tuesday, September 24, 2019 at 8a.m. PST/11a.m. EDT/4p.m. BST/5p.m. CEST.

Walter Boyle, MS, global head of Biostatistics and Programming at Synteract will address key questions and considerations on biostatistical tools that sponsors should assess before starting a rare disease trial. Boyle’s presentation will help to demystify the myriad of statistical methods available to minimize risk and maximize value.

Boyle has more than 15 years of experience analyzing, exploring, and explaining clinical and health care data across public health, life sciences, healthcare, and analytical software development. He will address positive, and potentially negative, ways advanced statistical concepts can impact clinical trials and how sponsors and vendors can work together to ask the right questions in advance of trial start-up.

“Each rare disease trial poses unique challenges based on the condition, trial requirements, and individual patient. Advanced biostatistical models help to provide mitigation strategies that can improve drug safety and accurate data collection,” says Boyle. “In this webinar, clinical professionals will gain greater insight into important questions to ask to make sure the right statistical concepts are used upfront in their rare disease trials.”

Biotech and pharma professionals can register for this webinar at this link: “Utilizing Inventive Biostatistical Methods to Enhance Rare Disease Trials.

About Synteract
“Bringing Clinical Trials to Life” represents Synteract’s commitment to engage with drug developers, patients, investigators, and regulatory experts, to bring insights to action and make better therapies a reality. Synteract supports biotech and pharma companies across all phases of drug development to help bring new medicines to market. Synteract has conducted nearly 4,000 studies on six continents and in more than 60 countries. It has contributed to more than 260 product approvals. Synteract offers a notable depth of therapeutic expertise in oncology, dermatology, neuro degenerative, pediatrics, and rare and orphan diseases. Connect on LinkedIn and Twitter.

# # #

CONTACT:
Beth Walsh
beth@clearpointagency.com
760-230-2424

x

Submit RFI / RFP

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

Contact Synteract

Tell us how to stay in touch with you:

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

Required

x

 

x

Download Resource

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required

x

To complete your download, please choose an option in the Internet Explorer pop-up window at the bottom of this browser.

x

Opt In

By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Synteract that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.

*Required